Fluconazole and related azole medicines are widely used against fungal infections, but drug resistance can undermine their effectiveness. Some Candida albicans isolates withstand treatment by activating cellular stress defenses. These defenses help the fungus cope with drug-induced damage and offer a possible point of intervention for restoring antifungal activity.
Directly blocking stress-response proteins is difficult because similar proteins perform essential functions in human cells, and some inhibitors can suppress immunity. An alternative approach is to disrupt the cellular resources that help resistant fungi withstand treatment. Iron is one such resource: it supports mitochondrial respiration and other processes needed for fungal growth and adaptation.
Researchers led by Wenqiang Chang and Hongxiang Lou at Shandong University and colleagues at collaborating institutions investigated whether existing medicines could exploit this vulnerability. The team screened 1,548 compounds from an approved-drug library and a natural-product collection. Three iron-binding compounds emerged as resistance-reversing candidates: eltrombopag, deferoxamine mesylate, and tannic acid. The study has been accepted for publication in Mycology.
Eltrombopag is already used for certain blood disorders. In laboratory tests with the resistant isolate CA632, adding 2 micrograms per milliliter of eltrombopag lowered the fluconazole concentration required to inhibit growth from more than 128 to 2 micrograms per milliliter. The other two chelators also enhanced fluconazole activity. These effects were observed in isolates with stress-response-dependent resistance; the compounds did not restore susceptibility in the tested isolates with resistance associated with drug-efflux-pump overexpression.
The results pointed to an important role for available iron. The researchers compared 21 resistant clinical isolates with nine susceptible isolates and found higher levels of readily available intracellular iron in the resistant group, both in standard culture and in serum-containing medium. Chelator treatment lowered this iron pool, while adding external iron abolished the resistance-reversing effect. Iron restriction was also accompanied by impaired mitochondrial respiration, lower cellular energy levels, and changes in membrane electrical potential. These observations identify cellular vulnerabilities associated with sensitization, although the causal contribution of each downstream change remains to be established.
The team then examined whether the laboratory findings translated to an infection model using wax moth larvae. Eltrombopag combined with fluconazole significantly improved survival and reduced fungal burden compared with either drug alone, with less extensive fungal involvement in tissue sections. Deferoxamine mesylate and tannic acid did not significantly improve survival over fluconazole alone under the tested conditions.
Together, the findings connect fungal iron availability with a specific form of azole resistance and identify a possible new use for an established medicine. Eltrombopag is a candidate for further investigation as an antifungal adjuvant. Studies in mammalian infection models are needed to evaluate efficacy, drug exposure, host iron balance, and potential interactions with fluconazole before clinical application can be considered.
Journal
Mycology: An International Journal on Fungal Biology
Article Title
Iron chelation by eltrombopag reverses stress-response-dependent azole resistance
Article Publication Date
16-Nov-2026